NCT04924881

Chinese Medicine for Patients With LCOVID-19 Symptoms

Status unknown Phase 2 Last updated 28 January 2022

What this trial tests

Phase 2 trial testing COVID Rehab Formula granules in Covid19 in 68 participants. Status unknown.

Timeline

1 January 2022

Primary endpoint
31 January 2023

30 June 2023

Quick facts

Lead sponsor	Chinese University of Hong Kong
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	68
Start date	1 January 2022
Primary completion	31 January 2023
Estimated completion	30 June 2023
Sites	1 location across Hong Kong

Drugs / interventions tested

• COVID Rehab Formula granules — full drug profile →
• Placebo granules

Conditions studied

• Covid19 — all drugs for Covid19 →

Sponsor

Chinese University of Hong Kong

Who can join

18 and older, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

COVID-19 has spread rapidly and now affects all over the world. On 11 March 2020, coronavirus disease 2019 (COVID-19) was declared a global pandemic by the World Health Organization (WHO).

Most of the infected people will develop mild to moderate illness, for example fever, cough, tiredness and joint pain etc. For some older people, and those with comorbidities like cardiovascular disease, diabetes, chronic respiratory disease, and malignancy are more likely to develop serious illness. Also long-term problems such as fatigue, breathlessness and joint pain experienced by survivors of COVID-19 after discharge from hospital.

Some clinical and pharmacological studies have suggested Traditional Chinese Medicine (TCM) has achieved remarkable therapeutic effect for active COVID cases of different severity during SARS epidemic in 2003. Also, some studies shown that using Chinese medicine interventions together with conventional treatment is more effective than using the conventional treatment alone in treating chronic fatigue syndrome.

Traditional Chinese Medicine (TCM) has a long history and played an important role in the prevention and treatment of several epidemic diseases. However, there is a lack of clinical study of using TCM to treat the residue symptom of COVID-19 recovered patients.

COVID-19 recovered patients will be screened and randomized into TCM group or placebo group for 8 weeks and followed by a post-treatment visits at week 12.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Chinese medicine for residual symptoms of COVID-19 recovered patients (long COVID)-A double-blind, randomized, and placebo-controlled clinical trial protocol.
   Sum CH, Ching JYL, Song T, Cheong PK, et al · · 2022 · cited 7× · PMID 36687403 · DOI 10.3389/fmed.2022.990639